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Abstract
Objective: Many complex diseases exhibit co-morbidities often requiring management 
by more than one health specialist. We examined cross-speciality issues that ultimately 
affect the health and wellbeing of patients with polycystic ovary syndrome (PCOS). PCOS 
was originally described as a reproductive condition but is now recognised to also be a 
metabolic and psychological condition affecting 8–13% of women of reproductive age. 
With a four-fold increased risk of type 2 diabetes (DM2), the Population Attributable 
Risk of DM2 that could be avoided if PCOS were eliminated is a substantial 19–28% of 
women of reproductive age. To determine the extent to which PCOS is an important 
consideration in diabetes development, we examined publications, funding, guidelines 
and predictors of risk of developing DM2.
Results: We found that the topic of PCOS appeared in specialist diabetes journals at only 
10% the rate seen in endocrinology journals – about 1 in 500 articles. We found research 
funding to be substantially less than for diabetes and found that diabetes guidelines 
and predictive tools for DM2 risk mostly ignore PCOS. This is surprising since insulin 
resistance in women with PCOS has a different aetiology and additionally women with 
PCOS are at increased risk of becoming overweight or obese – high risk factors for DM2.
Conclusions: We consider the causes of these concerning anomalies and discuss current 
activities to address the co-morbidities of PCOS, including the recent development of 
international guidelines, an international PCOS awareness program and potentially 
changing the name of PCOS to better reflect its metabolic consequences.
Introduction
Following the recent release of international guidelines 
for management of polycystic ovary syndrome (PCOS) 
(1) endorsed by 38 international organisations in 71 
countries, the research, clinical and consumer PCOS 
communities have highlighted the challenges caused by 
the poor recognition of the metabolic features of PCOS. 
To meet these challenges international multifaceted, 
multilingual education and translation/awareness 
programs are underway with free resources to be 
found at https://www.monash.edu/medicine/sphpm/
mchri/pcos. Here, we sought to identify and analyse 
some of the other problems that need to be addressed 
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to overcome the poor recognition of the metabolic 
features of PCOS.
PCOS is a chronic complex disorder that affects more 
than one in ten women, significantly impacting health 
and well-being (2, 3). The pathophysiology of PCOS is 
poorly understood and a US National Institute of Health 
(NIH) evidence-based consensus workshop has recognised 
that awareness of the condition is limited, while PCOS 
research is inadequate and poorly funded (4). PCOS is a 
reproductive and metabolic condition with psychological 
consequences (5). Women with PCOS suffer symptoms 
of excess androgen (hirsutism, acne, central adiposity), 
reproductive dysfunction (infertility, menstrual 
irregularity, miscarriage, pregnancy complications) and 
metabolic complications (6, 7). Metabolic features include 
insulin resistance (IR), compensatory hyperinsulinaemia 
and associated risk of gestational diabetes (GDM), impaired 
glucose tolerance, type 2 diabetes (DM2), non-alcoholic 
fatty liver disease (NAFLD), dyslipidaemia and increased 
risk factors for both cerebrovascular and cardiovascular 
disease (6, 7, 8, 9). Ultimately, anxiety, depression and 
distress are increased and quality of life is reduced (10, 11). 
As such, the syndrome is a significant cause of physical 
and emotional distress to sufferers and is a significant 
economic burden to individuals and governments (12).
Based on the Rotterdam criteria, the prevalence of 
PCOS in women of reproductive age is 8–13% (3, 13). 
Women with PCOS have a four-fold increased risk of DM2 
irrespective of their BMI and with a younger disease onset 
(14, 15). Using these figures, we calculate that the Population 
Attributable Risk (PAR = proportion exposed × (relative 
risk − 1)/1 + proportion exposed × (relative risk − 1)) is 
19.4% (PAR = 0.08 (4–1)/(1 + 0.08 (4–1))) to 28% (PAR = 0.13 
(4–1)/(1 + 0.13 (4–1))). Thus, the prevalence of DM2 in 
women of reproductive age would be 19–28% lower if 
PCOS could be eliminated. GDM is also increased 2–3-fold 
in PCOS (16), yet, risk prediction tools for both GDM and 
DM2 have traditionally not accounted for PCOS.
The true underpinnings of increased risk of DM2 in 
PCOS remain complex and somewhat unclear. On WHO 
criteria for IR (clamp-derived glucose infusion rate levels 
as less than the 25th centile of lean matched controls), a 
study in 73 women using gold standard clamp techniques 
showed that 75% of lean and 95% of obese women had 
IR compared to weight-matched controls (17). This was 
supported by a meta-analysis of clamp studies in PCOS 
where IR is clearly increased independently of BMI, yet, 
it is exacerbated by obesity (18). Inherent IR mechanisms 
in PCOS also appear to differ from those associated with 
DM2 or obesity (6, 19). Insulin-mediated glucose uptake 
in skeletal muscle and adipose tissue is affected by a post 
receptor defect in insulin signalling in PCOS (19), that is 
the subject of ongoing research.
With IR, GDM and DM2 being such major features 
of PCOS, the link between PCOS, diabetes and metabolic 
dysfunction appears to be under-appreciated. To explore 
this further, we analysed some of the barriers that have 
confronted clinical and basic research into PCOS and 
highlight some of the recent initiatives to address these 
issues.
Publications on PCOS
We first examined journals devoted to the topic of 
diabetes. We performed PubMed (https://www.ncbi.
nlm.nih.gov/pubmed) searches on the terms ‘polycystic’ 
OR ‘PCOS’ in diabetes journals selected from the top 
20 ranked journals by impact factor in Thompsons ISI’s 
category of ‘Endocrinology and Metabolism’ with the 
word ‘diabetes’ in the journal name (Table 1). We could 
find 0, 34, 36, 15 and 4 articles in total in Lancet Diabetes 
Endocrinology, Diabetes, Diabetes Care, Diabetologia and 
Diabetes Obesity Metabolism, respectively, at any time 
prior to the study end date of March, 2017. This equates 
to around one in every 500 articles addressing the topic of 
PCOS, which is more than 10-fold lower than in journals 
devoted to clinical endocrinology or clinical reproduction 
(Table  1). This is despite 6853 total articles on PCOS 
addressing insulin, IR or T2DM (searching on (polycystic 
ovary OR PCOS) AND (insulin OR diabetes) in PubMed). 
In summary, key relevant diabetes journals publish 
relatively little on this common condition affecting one 
in ten women and imparting a high risk of DM2 at a 
younger age.
Why is PCOS under-represented in diabetes journals? 
Without knowing the rates of submission and acceptance 
for relevant journals, it is not possible to assess where the 
challenges lie, and whether there may be a potential bias 
in handling of PCOS articles or if authors preferred other 
journals focused on endocrinology or reproduction. It 
might be a combination of both as of ‘the 8600 papers 
submitted to Diabetologia since 1 Jan 2013, only 17 articles 
had PCOS/polycystic in the title (i.e. 0.2%), suggesting that 
one of the main reasons for low penetrance of PCOS in the 
diabetes journals is that they are not being submitted very 
much’ (Editor of Diabetologia, unpublished observation). 
Poor funding of PCOS research has probably also led to 
fewer studies being published on PCOS (20) or perhaps 
studies have not been conducted to the standard required 
in diabetes journals. In any event, far fewer articles on 
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PCOS are published in the diabetes literature than in 
endocrinology and reproduction journals, and this rate 
appears to be lower than the high diabetes risk status 
would warrant.
Research funding of PCOS
Dr Ricardo Azziz and his colleagues examined funding 
by the NIH in the USA over 10  years. They identified 
that PCOS received substantially less funding than other 
conditions for which the prevalence, economic burden, 
metabolic morbidity and negative impact on quality of life 
was much less than PCOS (20). In Australia the National 
Health and Medical Research Council (NHMRC) is the 
premier funder of medical research and its main funding 
mechanism is by way of project grants with currently over 
600 granted per annum. Using NHMRC published data 
and searching the titles of the funded project grants for the 
terms ‘PCOS’ or ‘polycystic’, there were only nine funded 
project grants in 16  years (2003–2018) (21). Searching 
the term ‘diabetes’ in the titles of project grants for the 
same period we identified 196 funded grants. These data 
identify that that PCOS receives <5% of the funding that 
diabetes receives but contributes proportionately more to 
the prevalence of GDM and DM2.
Anecdotally, colleagues from other countries have 
found it strategically advantageous not to address PCOS 
issues when applying for research grants, but rather to 
examine broader issues that include PCOS as a subgroup. 
Additionally, whilst there are philanthropic organisations 
supporting research into many areas such as diabetes, 
cancer and cardiovascular diseases, we are unaware of any 
such foundations for PCOS. This raises the question as to 
why research into PCOS is so poorly funded. Part of the 
reason could be that the secondary pathologies associated 
with the syndrome, like obesity or DM2, take priority over 
PCOS which is perceived by many health professionals as 
primarily a reproductive disorder (22).
PCOS diagnosis and guidelines
PCOS was originally described as a reproductive condition 
(23), and it was not recognised that these patients had 
perturbed insulin and glucose handling until the 1980s 
(24). Additionally PCOS is multifactorial and there 
have been two major consensus meetings to define its 
diagnostic criteria referred to as the National Institute 
of Health (NIH) criteria (original) and the Rotterdam 
criteria (now NIH endorsed) (4). The first evidence-based 
guidelines in PCOS were produced in Australia in 2011 
(10) and international co-funded rigorous evidence-based 
guidelines have only recently been published (1).
The Rotterdam criteria stipulate two of the following 
symptoms (1) polycystic ovaries, (2) evidence of androgen 
excess and (3) oligo- or amenorrhea. These criteria were 
recently internationally endorsed (25) and are founded 
in evidence with the international evidence-based 
guideline for the assessment and management of PCOS 
Table 1 The numbers of articles on PCOS, the total number of articles published and the proportion of articles on PCOS.
Journal PCOS Total PCOS/total as %
Diabetes journals
 Lancet Diabetes and Endocrinology 0 924 0.0
 Diabetes Care 36 15,867 0.23
 Diabetes 34 15,713 0.22
 Diabetologia 15 11,062 0.14
 Diabetes Obesity Metabolism 4 2465 0.16
Clinical endocrinology journals
 Journal of Clinical Endocrinology and Metabolism 866 32,867 2.63
 European Journal of Endocrinology 162 5484 3.0
 Endocrine 71 3517 2.0
Basic endocrinology journals
 Journal of Endocrinology 61 15,042 0.40
 Endocrinology 98 37,317 0.26
Clinical reproduction journals
 Fertility and Sterility 1288 23,528 5.47
 Human Reproduction 732 13,935 5.3
Basic reproduction journals
 Reproduction 4 2853 0.1
 Biology of Reproduction 66 13,807 0.5
The data were collected in early 2017 and the search terms used were ‘PCOS’ and ‘polycystic’, and both the titles and abstracts were searched in PubMed. 
The numbers of articles include articles containing primary data and review articles.
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in adults. These criteria are supported by recent genome 
wide association data showing common genotypes across 
all diagnostic criteria (26). In women within 8  years of 
menarche, both (1) irregular cycles and (2) evidence 
of androgen excess are needed for diagnosis, whilst 
ultrasound detection of polycystic ovarian morphology 
was not recommended in diagnosis due to inaccuracy in 
this group (1).
PCOS has been recognised as a non-modifiable risk 
factor for diabetes, yet often PCOS was not considered in 
predictive tools for diabetes (27). However, some more 
recent predictive tools are taking PCOS into account (28). 
The research, clinical and consumer PCOS communities 
have highlighted the challenge that the metabolic features 
of PCOS are poorly recognised and an international 
PCOS awareness program is now established. Currently 
international multifaceted, multilingual education and 
translation/awareness programs are underway with 
free resources to be found at https://www.monash.edu/
medicine/sphpm/mchri/pcos.
Changing the name of PCOS
The name of PCOS does not indicate the full breadth of 
complications. Additionally, the term ‘polycystic ovary’ is 
a misnomer, and it is not necessary or sufficient to describe 
PCOS. A recent survey interviewed 105 clinicians and 57 
women diagnosed with PCOS to understand perceptions 
about the key clinical features of the syndrome (29). The 
majority of women and clinicians (86%, 90%) identified 
‘irregular periods’ as a key feature, with ‘hormonal 
imbalance’ (60%) as the next most popular. Incorrectly 
47% of women identified ‘ovarian cysts’ as the key feature. 
Almost half of the women (48%) found the name to be 
confusing (29).
In regard to the name, a NIH PCOS evidence-based 
workshop (4) stated ‘We believe the name ‘PCOS’ is a 
distraction and an impediment to progress. It causes 
confusion and is a barrier to effective education of 
clinicians and communication with the public and 
research funders. The name focuses on a criterion – 
polycystic ovarian morphology – which is neither 
necessary nor sufficient to diagnose the syndrome. We 
believe it is time to recognise the advances that have 
been made since the description of the syndrome by 
Irving F Stein Sr and Michael L Leventhal. It is time to 
expeditiously assign a name that reflects the complex 
metabolic, hypothalamic, pituitary, ovarian and adrenal 
interactions that characterise the syndrome and their 
reproductive implications. The right name will enhance 
recognition of this major public health issue for women, 
educational outreach, ‘branding’ and public relations and 
will assist in expanding research support. There is now 
an international dialogue to drive a name change with a 
view to increasing understanding of the prevalence and 
its diverse key features, including DM2 (30).
Conclusions
Based upon the prevalence of PCOS and its seriously high 
risk factors for IR, GDM and DM2, it is clear that PCOS has 
not received the attention it warrants, especially in the 
diabetes arena. One wonders if the metabolic phenotypes 
of PCOS had been recognised from the outset and if the 
syndrome had not been named incorrectly or better named 
to reflect its metabolic phenotype, PCOS might have been 
a higher funding and publishing priority. It is not possible 
from our analyses to discern if the low emphasis on PCOS 
within the diabetes arena is due to specific issues around 
PCOS or if this is simply an issue around complex diseases 
requiring multi-disciplinary approaches wherein one 
discipline rates the disease less highly than another. Going 
forward it will be informative to track how the mental health 
arena regards PCOS now that it has been recognised as a risk 
factor for issues involving mental health and wellbeing. In 
the meantime, we advocate that PCOS needs to be better 
recognised, including by the diabetes community, for its 
substantial and unique metabolic features and its important 
contribution to the development of DM2.
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